FDA official calls UniQure's Huntington's disease treatment a failure [Yahoo! Finance]
uniQure N.V. - Ordinary Shares (QURE)
Last uniqure n.v. - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
uniqure.com/investors-newsroom/overview.php
Company Research
Source: Yahoo! Finance
a "failed product" in ?a conference call with media members on Thursday, casting further ?doubt on the prospects of the gene therapy. On Monday, the Dutch drugmaker said the U.S. Food ?and Drug Administration had called for a new study to support the approval of its gene therapy for the rare, inherited neurodegenerative disorder and rejected its most recent trial for not including participants given a placebo. The FDA official, who ?spoke on the condition ?of anonymity, said a trial run by the company several years ago with a placebo design "was stone cold negative. We ?have a failed product here." The call followed criticism from UniQure and patient advocate groups of the FDA's request. The official also accused UniQure of making a "distorted or manipulated ?comparison" ?in how it presented data for the ?treatment. UniQure declined to comment on ?the FDA official's remarks. The company's U.S.-listed shares rose on Thursday ahead of the media briefing by more than 20% afte
Show less
Read more
Impact Snapshot
Event Time:
QURE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QURE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QURE alerts
High impacting uniQure N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
QURE
News
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QUREPR Newswire
- Holzer & Holzer, LLC Reminds QURE Investors of the April 13, 2026 Lead Plaintiff Deadline in the uniQure N.V. Securities Class ActionGlobeNewswire
- FDA official calls UniQure's gene therapy a ‘failed' treatment for Huntington's disease [CNBC]CNBC
- Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire
- Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. InvestorsGlobeNewswire
QURE
Earnings
- 11/10/25 - Miss
QURE
Sec Filings
- 3/4/26 - Form 144
- 3/4/26 - Form 144
- 3/4/26 - Form 144
- QURE's page on the SEC website